Not Much Love for ARKF

If you don't know Cathie Woods and her ETFs by now, what rock have you been sleeping under when all these rocks are getting unturned. ARKG recently made the biggest moves as the genomics sector might yield higher returns according to Cathie. There is a lot of overlap between each fund, so I'm unsure if you can compare each fund side by side and say "ARKG will be over $150 soon because ARKK and ARKW are" or not.

I'm primarily a trader because I can currently make more money with options leverage, than buying and holding. I think for smaller accounts like me, the pay off and risk is better in the short term, especially in this extreme bull market. If you're a long term investor with a lower risk allocation and less time on your hands, buying and holding is a no brainer. Trading also comes with a steep learning curve and there's a price to pay.

But, I digress, AKRF and ARKQ are the two funds that are lagging behind, not counting IZRL and PRNT (they're indexed not active). This means ARKF (especially because it has better options volume and is cheaper) has more room to grow with all the buzz happening in the banking and crypto industry rn. Even JPM admits they're fucked if they don't do anything.

D I S R U P T I V E B A N K I N G

All the ARKs look bound for some sort of small correction, especially ARKF on the 4Hr time frame. Long dated call options on some ETFs are practically free money right now.

Fundamental AnalysisTechnical IndicatorsTrend Analysis

Publikasi terkait

Pernyataan Penyangkalan